DAAN Biotherapeutics signed an exclusive licensing deal with LigaChem Biosciences for a tumor-targeting antibody for ADC development

The partnership enhances LigaChem’s ADC program using DAAN’s advanced antibody technology

DAAN has built a proprietary antibody pipeline targeting solid tumors through a collaboration with OmniAb

The company focuses on discovering and developing next-gen antibodies for solid cancers